dopaminergic agonist

出典: meddic

ドパミン作動薬

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • The effect of dopamine on adult hippocampal neurogenesis.
  • Takamura N1, Nakagawa S2, Masuda T3, Boku S4, Kato A4, Song N4, An Y4, Kitaichi Y4, Inoue T4, Koyama T4, Kusumi I4.Author information 1Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan.2Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan. Electronic address: snakaga@med.hokudai.ac.jp.3Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan.4Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.AbstractCumulative studies indicated that adult hippocampal neurogenesis might be involved in the action mechanism of antidepressant drugs and/or the pathophysiology of depression. Dopamine (DA) is involved in the regulation of motivation, volition, interest/pleasure, and attention/concentration, all of which are likely to be impaired in depressed patients. Several previous reports suggest that depression may often be accompanied by a relative hypo-dopaminergic state, and some DA receptor agonists are beneficial effects in the treatment for refractory and bipolar depression. In the present study, to clarify the direct effect of DA on neural progenitor cells, we examined the effect of DA on the proliferation of adult rat dentate gyrus-derived neural precursor cells (ADPs). In addition, we examined the effect of DA receptor agonists on adult rat hippocampal neurogenesis in vivo. Results showed that DA promoted the increase of ADPs via D1-like receptor and D1-like receptor agonist promoted the survival of newborn cells in the adult hippocampus. On the contrary, D2-like receptor agonist did not affect both proliferation and survival. These results suggested that DA might play, at least in part, a role in adult hippocampal neurogenesis via D1-like receptor and the activation of D1-like receptor has a therapeutic potential for depression.
  • Progress in neuro-psychopharmacology & biological psychiatry.Prog Neuropsychopharmacol Biol Psychiatry.2014 Apr 3;50:116-24. doi: 10.1016/j.pnpbp.2013.12.011. Epub 2013 Dec 26.
  • Cumulative studies indicated that adult hippocampal neurogenesis might be involved in the action mechanism of antidepressant drugs and/or the pathophysiology of depression. Dopamine (DA) is involved in the regulation of motivation, volition, interest/pleasure, and attention/concentration, all of whi
  • PMID 24374069
  • Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
  • Ouachikh O1, Dieb W1, Durif F2, Hafidi A3.Author information 1Clermont Université, Université d'Auvergne, EA7280, Laboratoire de Neuropsychopharmacologie des systèmes dopaminergiques sous corticaux, Clermont-Ferrand, France.2Clermont Université, Université d'Auvergne, EA7280, Laboratoire de Neuropsychopharmacologie des systèmes dopaminergiques sous corticaux, Clermont-Ferrand, France; CHU Clermont-Ferrand, Service de Neurologie, 63000 Clermont-Ferrand, France.3Clermont Université, Université d'Auvergne, EA7280, Laboratoire de Neuropsychopharmacologie des systèmes dopaminergiques sous corticaux, Clermont-Ferrand, France. Electronic address: azhafidi@univ-bpclermont.fr.AbstractDopamine dysregulation syndrome in Parkinson's disease has been attributed to dopamine replacement therapies and/or a lesion of the dopaminergic system. Dopaminergic neuronal loss targets the substantia nigra and the ventral tegmental area (VTA). We hypothesize that dopamine replacement therapy is responsible for the potential reinforcement effect in Parkinson's disease, by acting on the neuronal reward circuitry. We previously demonstrated that the posterior (p) VTA, which projects to the nucleus accumbens (NAc), is implicated in the motivational effect of dopamine receptor agonists in 6-OHDA bilateral pVTA-lesioned drug-free animals. In the present study we investigated the implication of the anterior (a) VTA in the potential reinforcement effect of dopamine receptor agonists. Using the conditioned place preference (CPP) behavioral paradigm, we investigated the motivational effects of dopamine receptor agonists (bromocriptine and pramipexole), and cocaine in rats with a 6-OHDA bilateral lesion of the aVTA. Bromocriptine and pramipexole did not induce a significant CPP at 1mg/kg in both sham and bilateral 6-OHDA-lesioned rats. However bromocriptine induced CPP only at a dose of 3mg/kg in both animal groups. Moreover cocaine, which is known to increase dopamine release, induced reinforcing effects in both 6-OHDA-lesioned and sham rats. Our data show a lack of involvement of aVTA dopamine neurons in the motivational effects of bromocriptine, pramipexole and cocaine.
  • Behavioural brain research.Behav Brain Res.2014 Apr 1;262:1-7. doi: 10.1016/j.bbr.2013.12.021. Epub 2013 Dec 19.
  • Dopamine dysregulation syndrome in Parkinson's disease has been attributed to dopamine replacement therapies and/or a lesion of the dopaminergic system. Dopaminergic neuronal loss targets the substantia nigra and the ventral tegmental area (VTA). We hypothesize that dopamine replacement therapy is r
  • PMID 24361908
  • What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
  • Hornyak M1, Scholz H2, Kohnen R3, Bengel J4, Kassubek J5, Trenkwalder C6.Author information 1Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany; Department of Psychiatry and Psychotherapy, University Medical Center, Hauptstrasse 6, 79095 Freiburg, Germany. Electronic address: hornyak@gmx.de.2Department of Psychiatry and Psychotherapy, University Medical Center, Hauptstrasse 6, 79095 Freiburg, Germany. Electronic address: scholz.hanna@gmx.de.3RPS Research Germany GmbH, 520 Virginia Drive, Fort Washington, PA 19034, USA; Department of Psychology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany. Electronic address: Rkohnen@rpsweb.com.4Institute for Psychology, University of Freiburg, Engelberger Strasse 41, 79085 Freiburg, Germany. Electronic address: Bengel@psychologie.uni-freiburg.de.5Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.6Paracelsus-Elena-Klinik, Center for Movements Disorders, Klinikstrasse 16, 34128 Kassel, Germany; University of Goettingen, 37073 Göttingen, Germany. Electronic address: trenkwalder@pk-mx.de.AbstractBACKGROUND: At the time of writing only dopamine agonists are licensed for the treatment of restless legs syndrome (RLS) in various countries, but randomized controlled trials (RCTs) have been performed with other treatments. We performed comprehensive meta-analyses and indirect comparisons of RCTs for all currently recommended treatments of RLS.
  • Sleep medicine reviews.Sleep Med Rev.2014 Apr;18(2):153-164. doi: 10.1016/j.smrv.2013.03.004. Epub 2013 Jun 6.
  • BACKGROUND: At the time of writing only dopamine agonists are licensed for the treatment of restless legs syndrome (RLS) in various countries, but randomized controlled trials (RCTs) have been performed with other treatments. We performed comprehensive meta-analyses and indirect comparisons of RCTs
  • PMID 23746768

和文文献

  • パーキンソン病の気分障害
  • Effect of repeated oral administration of Bifidobacterium longum BB536 on apomorphine-induced rearing behavior in mice
  • Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist

関連リンク

Quinagolide Quinagolide is obtained by chemical synthesis. Its chemical structure has similarities with that of ergot derivatives and that of apomorphine. It is a specific agonist of D2 dopaminergic receptors. Its principal effect is to ...
1. Drugs Aging. 2013 Aug;30(8):587-92. doi: 10.1007/s40266-013-0090-z. Dopamine agonist withdrawal syndrome: implications for patient care. Nirenberg MJ(1). Author information: (1)Department of Neurology ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元ドパミン作動薬
関連記事agonist」「dopaminergic

ドパミン作動薬」

  [★]

dopamine agonistdopaminergic agonistdopaminergic agent, dopaminergic drug, dopamine receptor agonist, dopamine receptor stimulant
ドパミン作用薬、ドパミン刺激薬、ドパミン受容体作用薬ドパミン受容体作動薬ドパミン受容体刺激薬ドパミンアゴニスト
ドパミン
[show details]
  • ドパミン作動薬:レボドパ、ブロモクリプチン、インスリン、アルギニン、グルカゴン、プロプラノール(QB.D-254)


agonist」

  [★] 作動薬

WordNet   license wordnet

「(biochemistry) a drug that can combine with a receptor on a cell to produce a physiological reaction」

WordNet   license wordnet

「a muscle that contracts while another relaxes; "when bending the elbow the biceps are the agonist"」

WordNet   license wordnet

「someone involved in a contest or battle (as in an agon)」


dopaminergic」

  [★]

  • adj.
  • ドパミン作動性の、ドーパミン作動性の、ドパミン系の、ドーパミン系の




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡